Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

[1]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[2]  R. Fisher,et al.  Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Brian O'Sullivan,et al.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Lassen.  The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  D. Thwaites,et al.  Vorsprung durch Technik: evolution, implementation, QA and safety of new technology in radiotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  M. Sundvall,et al.  Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Claire Lemer,et al.  An international review of patient safety measures in radiotherapy practice. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  J. Hainsworth,et al.  Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck , 2009, Cancer.

[10]  F. Hirsch,et al.  Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Weichselbaum,et al.  Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Dancey,et al.  Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Bentzen,et al.  Evaluation of early and late toxicities in chemoradiation trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Leitão,et al.  High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma , 2007, European Archives of Oto-Rhino-Laryngology.

[15]  Mechthild Krause,et al.  EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Suzanne L Wolden,et al.  Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[18]  K. Dietz,et al.  Bmc Cancer , 2022 .

[19]  E. Vokes,et al.  Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.

[20]  J. Overgaard,et al.  Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  K Kian Ang,et al.  Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. , 2004, International journal of radiation oncology, biology, physics.

[22]  Torben Steiniche,et al.  The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. , 2004, International journal of radiation oncology, biology, physics.

[23]  K. Ang,et al.  CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  K. Ang,et al.  Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings , 2003, International journal of radiation biology.

[25]  E. Vokes,et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[27]  V Grégoire,et al.  Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[29]  K. Ang,et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  A. Huang,et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.

[31]  D. Hollywood,et al.  Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[33]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.